Skip to content

Datacentrex, Inc. DTCX Acquired in-process research and development

Acquired in-process research and development at other companies

CTO
Citius Oncology, Inc.CTOR
$40M+2,393%
MAG
MagneraMAGN
$5M+53.8%
Smith & Wesson Brands, Inc. logo
Smith & Wesson Brands, Inc.SWBI
$0
NVE Corporation logo
NVE CorporationNVEC
$771.2K-25.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
$150M
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$8.09M-32.3%

Other financials

Income statement

See full
Revenue$2.2M+1,265%
Gross profit$512.9K+513%
Operating income-$5.0M-1,531%
Net income-$6.2M-1,893%
EPS (diluted)-$0.20+9.1%

Balance sheet

See full
Cash & equivalents$42.5M+4,003%
Total equity$79.2M+349%
Total assets$79.4M+2,397%

Cash flow

See full
Operating cash flow-$3.2M-158%
CapEx$25.9M+262,610%
Free cash flow-$27.4M-1,023%

Valuation

See full
Market cap$69.2M+15.2%
P/S7.6×

Profitability

See full
Operating margin-9,494.1%
Net margin-9,150.1%
FCF margin-33,510.2%

Returns & leverage

See full
Return on equity-57.5%-28.0pp
Current ratio229.9×+227×

Where this comes from

Reported directly by Datacentrex, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfIntangibleAssets.

The official record: Datacentrex, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Datacentrex, Inc. 's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Datacentrex, Inc. 's acquired in-process research and development?
Datacentrex, Inc. (DTCX) reported acquired in-process research and development of $31.87K in Q1 2026.
What does acquired in-process research and development mean?
This metric represents the cash consideration paid to acquire research and development projects that have not yet reached technological feasibility. It reflects the company's strategy of buying innovation rather than developing it internally. Investors analyze this to evaluate the cost and risk associated with inorganic growth and R&D pipeline expansion.